Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Public ClinicalTrials.gov record NCT05163223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
Study identification
- NCT ID
- NCT05163223
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Aston Sci. Inc.
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- AST-301(pNGVL3-hICD) Biological
- rhuGM-CSF Drug
- Placebo Drug
- Pembrolizumab Drug
- Capecitabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2022
- Primary completion
- May 30, 2024
- Completion
- May 30, 2024
- Last update posted
- Jun 16, 2024
2022 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Centers | Chandler | Arizona | 85224 | — |
| Scripps Health | La Jolla | California | 92037 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | — |
| Nebraska Cancer Specialist | Omaha | Nebraska | 68130 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43623 | — |
| Toledo Clinic Cancer Center | Toledo | Ohio | 43623 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05163223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05163223 live on ClinicalTrials.gov.